| Autor: |
Bohjanen KA; Department of Dermatology, University of Minnesota Medical School, USA., Prawer SE |
| Jazyk: |
angličtina |
| Zdroj: |
Minnesota medicine [Minn Med] 2004 Mar; Vol. 87 (3), pp. 34-6. |
| Abstrakt: |
Psoriasis is a common cutaneous disease that can have a profound effect on an individual's life. New biologic drugs--proteins that are synthesized using recombinant DNA technology to mimic naturally occurring molecules and that selectively target the immune system--have changed the paradigm for treating this disease. We review 4 biologic drugs that are either currently FDA approved or in phase 3 studies: Alefacept (Amevive) and efalizumab (Raptiva), which are T-cell modulators; etanercept (Enbrel), a soluble TNF receptor; and infliximab (Remicade), an anti-TNF monoclonal antibody. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
